Brief: Monte Rosa Therapeutics And Yeda Announce License And Research Collaboration
25/01/2022 13:16
Jan 25 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS AND YEDA ANNOUNCE LICENSE AND
RESEARCH
COLLABORATION TO ACCELERATE DISCOVERY OF NOVEL COVALENT
MOLECULAR GLUE DEGRADERS
Source text for Eikon: ID:nGNX8fcZTh
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million